Literature DB >> 9166318

Misoprostol for medical evacuation of early pregnancy failure.

M D Creinin1, R Moyer, R Guido.   

Abstract

OBJECTIVE: To determine whether misoprostol (a prostaglandin E1 analogue) 400 micrograms orally (group 1) or 800 micrograms vaginally (group 2) will cause complete uterine evacuation in women with early pregnancy failure.
METHODS: Twenty subjects were recruited for a prospective, non-blinded, randomized clinical trial. Early pregnancy failure was diagnosed by transvaginal ultrasound examination; only women with a closed cervical os and minimal vaginal bleeding were enrolled. Subjects returned 24 hours after misoprostol administration for a transvaginal ultrasound examination. If the gestational sac was still present, the misoprostol dose was repeated and the subject returned again 24 hours later. Subjects who failed to expel the pregnancy were offered a suction curettage.
RESULTS: Twelve and eight women were randomized to groups 1 and 2, respectively. Complete uterine evacuation occurred in three of 12 [25%, 95% confidence interval (CI) 1%, 50%] and seven of eight (88%, 95% CI 65%, 100%, P = .010) subjects in groups 1 and 2, respectively. Vomiting occurred in 30% and 13%, respectively, and diarrhea in 50% and 38%, respectively.
CONCLUSION: Vaginal misoprostol 800 micrograms is more effective than oral misoprostol 400 micrograms for uterine evacuation of early pregnancy failure and may be an effective alternative to dilation and curettage.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9166318     DOI: 10.1016/s0029-7844(97)81438-x

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  9 in total

1.  Endometrial thickness after misoprostol use for early pregnancy failure.

Authors:  M D Creinin; B Harwood; R S Guido; M C Fox; J Zhang
Journal:  Int J Gynaecol Obstet       Date:  2004-07       Impact factor: 3.561

2.  A Comparative Study to Evaluate the Efficacy of Vaginal vs Oral Prostaglandin E1 Analogue (Misoprostol) in Management of First Trimester Missed Abortion.

Authors:  Sheeba Marwah; Supriya Gupta; Neera Parothi Batra; Vidhu Bhasin; Veena Sarna; Nirlep Kaur
Journal:  J Clin Diagn Res       Date:  2016-05-01

3.  Factors related to successful misoprostol treatment for early pregnancy failure.

Authors:  Mitchell D Creinin; Xiangke Huang; Carolyn Westhoff; Kurt Barnhart; Jerry M Gilles; Jun Zhang
Journal:  Obstet Gynecol       Date:  2006-04       Impact factor: 7.661

4.  Treatment patterns for early pregnancy failure in Michigan.

Authors:  Vanessa K Dalton; Lisa H Harris; Sarah J Clark; Lisa Cohn; Ken Guire; A Mark Fendrick
Journal:  J Womens Health (Larchmt)       Date:  2009-06       Impact factor: 2.681

Review 5.  Medical treatments for incomplete miscarriage (less than 24 weeks).

Authors:  James P Neilson; Gillian Ml Gyte; Martha Hickey; Juan C Vazquez; Lixia Dou
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

6.  A randomized trial of saline solution-moistened misoprostol versus dry misoprostol for first-trimester pregnancy failure.

Authors:  Jerry M Gilles; Mitchell D Creinin; Kurt Barnhart; Carolyn Westhoff; Margaret M Frederick; Jun Zhang
Journal:  Am J Obstet Gynecol       Date:  2004-02       Impact factor: 8.661

Review 7.  Medical treatments for incomplete miscarriage.

Authors:  Caron Kim; Sharmani Barnard; James P Neilson; Martha Hickey; Juan C Vazquez; Lixia Dou
Journal:  Cochrane Database Syst Rev       Date:  2017-01-31

8.  Medical treatment for early fetal death (less than 24 weeks).

Authors:  Marike Lemmers; Marianne Ac Verschoor; Bobae Veronica Kim; Martha Hickey; Juan C Vazquez; Ben Willem J Mol; James P Neilson
Journal:  Cochrane Database Syst Rev       Date:  2019-06-17

9.  Methods for managing miscarriage: a network meta-analysis.

Authors:  Jay Ghosh; Argyro Papadopoulou; Adam J Devall; Hannah C Jeffery; Leanne E Beeson; Vivian Do; Malcolm J Price; Aurelio Tobias; Özge Tunçalp; Antonella Lavelanet; Ahmet Metin Gülmezoglu; Arri Coomarasamy; Ioannis D Gallos
Journal:  Cochrane Database Syst Rev       Date:  2021-06-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.